Analyst Conference Summaries

Biotechnology Investor Aids

Celldex Therapeutics
CLDX

Conference date: May 6, 2021 press release only

Celldex Jumps on CDX-0159 Data [June 15, 2020 @ Seeking Alpha]

Celldex Breast Cancer Phase 2 Study of glembatumumab vedotin fails [April 16, 2018]

Celldex Value Depends on Coming Data [February 8, 2018 @ Seeking Alpha]

Celldex Set to Bounce Back [April 15, 2015 @ Seeking Alpha]

2021
Celldex
Q1 2021
Press Release
     
May 6, 2021      
2020
Celldex
Q1 2020
Celldex
Q2 2020
Celldex
Q3 2020
Celldex
Q4 2020
May 6, 2020 Aug. 6, 2020 Nov. 5, 2020 March 29, 2021
2019
Celldex
Q1 2019
Celldex
Q2 2019
Celldex
Q3 2019
Celldex
Q4 2019
May 7, 2019 August 7, 2019 Nov. 11, 2019 March 26, 2020
2018
Celldex
Q4 2018
May 10, 2018
August 8, 2018
Nov. 7, 2018
March 7, 2019
2017
May 9, 2017
August 8, 2017
Nov. 11, 2017
March 7, 2018
2016
05/05/2016
08/08/2016
11/07/2016
03/14/2017
2015

Celldex Q2
analyst call
not available  
08/10/2015
11/05/2015
02/25/2016

Celldex Therapeutics (CLDX) is a biotechnology company developing therapies for cancers.

Celldex Therapeutics web site

but did until 9/16/2020

 

Search

More Analyst Conference Pages:

 AGEN
 AGIO
 ALNY
 ALXN
 AMAT
 AMGN
 APRE
 ARWR
 BIIB
 BMY
 CLDX
 CLSN
 DRNA
 EPZM
 GILD
 GLYC
 ILMN
 INO
 IONS
 INCY
 ISRG
 MCHP
 MRNA
 PLX
 REGN
 RNA
 SAGE
 SGEN
 SYRS
 VBLT
 VSTM
 XLRN

 
 

Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. This is investment journalism, not financial advice.

Copyright 2021 William P. Meyers